Zoetis Inc (ZTS) Shares Bought by Wendell David Associates Inc.
Wendell David Associates Inc. lifted its stake in shares of Zoetis Inc (NYSE:ZTS) by 8.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,300 shares of the company’s stock after buying an additional 800 shares during the period. Wendell David Associates Inc.’s holdings in Zoetis were worth $742,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of ZTS. Franklin Resources Inc. increased its holdings in Zoetis by 7.7% in the second quarter. Franklin Resources Inc. now owns 11,349 shares of the company’s stock valued at $708,000 after purchasing an additional 816 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in Zoetis by 16.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares during the period. Fiera Capital Corp acquired a new stake in Zoetis in the second quarter valued at $1,184,000. BT Investment Management Ltd acquired a new stake in Zoetis in the second quarter valued at $565,000. Finally, PNC Financial Services Group Inc. increased its holdings in Zoetis by 4.7% in the second quarter. PNC Financial Services Group Inc. now owns 188,266 shares of the company’s stock valued at $11,745,000 after purchasing an additional 8,528 shares during the period. Institutional investors and hedge funds own 93.14% of the company’s stock.
Shares of Zoetis Inc (NYSE ZTS) opened at $75.54 on Wednesday. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The company has a market cap of $36,736.66, a price-to-earnings ratio of 39.76, a price-to-earnings-growth ratio of 1.90 and a beta of 1.06. Zoetis Inc has a 1 year low of $52.00 and a 1 year high of $76.40.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be given a dividend of $0.126 per share. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a yield of 0.67%. This is a boost from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio is 22.11%.
A number of analysts recently weighed in on the company. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a report on Thursday, October 12th. BidaskClub downgraded Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. BMO Capital Markets increased their price objective on Zoetis to $78.00 and gave the company a “market perform” rating in a report on Tuesday, January 9th. Craig Hallum restated a “buy” rating and issued a $85.00 price objective (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Finally, Cantor Fitzgerald set a $85.00 price objective on Zoetis and gave the company a “buy” rating in a report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company. Zoetis currently has an average rating of “Buy” and a consensus target price of $73.00.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.